Moxidectin

CHEMBL2104415 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
639.8 g/mol
LogP
4.3
Phase
4

An antiparasitic agent used to treat onchocerciasis (river blindness) and is also used in veterinary medicine against a wide range of internal and external parasites. It works by activating glutamate-gated chloride channels in parasites, causing paralysis and death.

Peso Molecular

639,8000 g/mol

LogP

4,30

TPSA

116,00 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C

InChI

InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1

Molecular Formula

C37H53NO8

HBD / HBA

2 / 9

Ligações Rotacionáveis

3

Átomos Pesados

46

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An antiparasitic agent used to treat onchocerciasis (river blindness) and is also used in veterinary medicine against a wide range of internal and external parasites. It works by activating glutamate-gated chloride channels in parasites, causing paralysis and death.

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Yes, Moxidectin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2104415. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9832912. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.